A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

Fitzgerald, Kevin, White, Suellen, Borodovsky, Anna, Bettencourt, Brian R., Strahs, Andrew, Clausen, Valerie, Wijngaard, Peter, Horton, Jay D., Taubel, Jorg, Brooks, Ashley, Fernando, Chamikara, Kauffman, Robert S., Kallend, David, Vaishnaw, Akshay, Simon, Amy·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1609243

Cited by (775)

Items 501–600 of 775

Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Muntaser Omari, Mohammad Alkhalil · 2024 · Journal of Cardiovascular Development and Disease
Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
Giuseppe Cicala, Michelangelo Rottura, Viviana Maria Gianguzzo, Federica Cristiano, Selene Francesca Anna Drago, Giovanni Pallio, Natasha Irrera, Egidio Imbalzano, Edoardo Spina, Vincenzo Arcoraci · 2024 · Pharmaceuticals
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events
Masashi Fujino, Giuseppe Di Giovanni, Stephen James Nicholls · 2024 · Journal of Atherosclerosis and Thrombosis
Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease
Isabel N. Schellinger, Angelika Dannert, Karin Mattern, Uwe Raaz, Philip S. Tsao · 2021 · Frontiers in Cardiovascular Medicine
siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery
Mei Lu, Mengjie Zhang, Bo Hu, Yuanyu Huang · 2021 · Methods in molecular biology
Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias
Fabiana Hanna Rached, Raul Dias Santos · 2021 · Current Cardiology Reports
Evolocumab for the treatment of hypercholesterolemia
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu · 2017 · Expert Opinion on Biological Therapy
Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering
Daniel Kirchhofer, Daniel J. Burdick, Nicholas J. Skelton, Yingnan Zhang, Mark H. Ultsch · 2020 · Biochemical Society Transactions
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Yajnavalka Banerjee, Angelo Maria Patti, Rosaria Vincenza Giglio, Marcello Ciaccio, Suhina Vichithran, Shemima Faisal, Anca Pantea Stoian, Ali Abbas Rizvi, Manfredi Rizzo · 2023 · Journal of Diabetes and its Complications
Progress of research on dyslipidemia accompanied by nephrotic syndrome
Min Tao, Haiping Wang, Jing Sun, Jing Tian · 2020 · Chronic Diseases and Translational Medicine
The Medicinal Chemistry of Antisense Oligonucleotides
Jonathan K. Watts · 2018 · Wiley eBooks
RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management
Abbas Mohammadi, Azin Karimian, Kasra Shokri, Ashkan Mohammadi, Nazanin Hazhir Karzar, Rayeheh Bahar, Azar Radfar, Mohammadreza Pakyari, Behnam N. Tehrani · 2025 · Journal of Cardiovascular Translational Research
Molecular mechanisms and targeted therapy of progranulin in metabolic diseases
Xiaoxia Wang, Yonglin Liang, Fan Yang, Yangyang Shi, Ruiwen Shao, Ruge Jing, Tong Yang, Qiao Chu, Dong An, Zhou Qi et al. · 2025 · Frontiers in Endocrinology
Chemical Modifications in Nucleic Acid Therapeutics
Kim A. Lennox, Rebecca C. Young, Mark A. Behlke · 2025 · Methods in molecular biology
The evolving therapeutic landscape of PCSK9 inhibition
Brett Stephen Mansfield, Yakubu O. Bene-Alhasan, Christie Mitchell Ballantyne, Frederick Johan Raal · 2026 · Atherosclerosis
Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease
Philippe Gabríel Steg, Shaun G. Goodman, J. Wouter Jukema, Pieter Martens, Andreas Zirlik, Deepak L. Bhatt, Venu Menon, Michael J. Szarek, Anastasia Lesogor, Christian Stratz et al. · 2026 · American Heart Journal
A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia
Eyas Al Mousa, Sayer I. Al-Azzam, Mohammad Araydah, Reema A. Karasneh, Mohammad A. Ghnaimat, Hanna K. Al-Makhamreh, Abdelkarim Khawaldeh, Muneer Ali Abu Al-Samen, JIHAD A. HADDAD, Said Al Najjar et al. · 2023 · Journal of Clinical Medicine
The Future of CRISPR Applications in the Lab, the Clinic and Society
Soren H. Hough, Ayokunmi Ajetunmobi · 2017 · Advances in experimental medicine and biology
Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease
Erica P. Young, Nathan O. Stitziel · 2018 · Annual Review of Medicine
Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension
Guido M. Grassi, Rita Del Pinto, Claudia Agabiti Rosei, Davide Agnoletti, Claudio Borghi, Arrigo F.G. Cicero, Carolina De Ciuceis, Giovambattista Desideri, Davide Grassi, María Lorenza Muiesan et al. · 2022 · High Blood Pressure & Cardiovascular Prevention
Target discovery using biobanks and human genetics
Michael A. Hicks, Claire Hou, Arya Iranmehr, Krisztina Marosi, Ewen F. Kirkness · 2019 · Drug Discovery Today
Recent insights into low-density lipoprotein metabolism and therapy
Angela Pirillo, Alberico Luigi Catapano, Giuseppe Danilo Norata · 2020 · Current Opinion in Clinical Nutrition & Metabolic Care
Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists
Abdullah Jahangir, Syeda Sahra, Michael Krzyzak · 2021 · Cureus
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Theodosios D. Filippatos, Angelos Liontos, Eliza C. Christopoulou, Moses Elisaf · 2018 · Current Vascular Pharmacology
Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)
Li, Bing, Chen, Yan, Zhang, Yongyi, Qian, Mengying, Shan, Qing, Qian, Jiao, Guo, Jinmin · 2026 · Expert Opinion on Drug Safety
The Potential of RNA Therapeutics in Treating Cardiovascular Disease
Gayatri Mainkar, Matteo Ghiringhelli, Lior Zangi · 2025 · Drugs
Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation
Kshipra Pandey, Sneha Jha, Loka Bikash Chaliha, Haren B. Gosai, Ritu Patel · 2026 · Frontiers in Nanotechnology
Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions
Reza Parvan, Joseph Pierre Aboumsallem, Wouter C. Meijers, Rudolf A. de Boer, A.H. Jan Danser · 2024 · European Journal of Pharmacology
The Safety Profile of Inclisiran in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis
Maliha, Maisha, Satish, Vikyath, Kumar, Sriram Sunil, Chi, Kuan Yu, Shama, Nishat, Kharawala, Amrin, Duarte, Gustavo, Li, Weijia, Purkayastha, Sutopu, Mangeshkar, Shaunak et al. · 2025 · Healthcare
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
Song Liu, Xingjin Wang, Jiaqiang Hu, Chen Zhao, Xiaoli Qin · 2025 · Diabetes Obesity and Metabolism
2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid
Hack‐Lyoung Kim, Jung‐Joon Cha, Sang‐Hak Lee · 2025 · Journal of Lipid and Atherosclerosis
Current Evidence and Future Directions of PCSK9 Inhibition
Jiaqian Xu, Michael David Shapiro · 2021 · US Cardiology Review
Selective modulator of nuclear receptor PPARγ with reduced adipogenic potential ameliorates experimental nephrotic syndrome
Claire Bryant, Galen C. Rask, Amanda P. Waller, Amy Webb, Marina Galdino da Rocha Pitta, Angélica Amorim Amato, Rachel E. Cianciolo, Rajgopal Govindarajan, Brian Becknell, Bryce A. Kerlin et al. · 2022 · iScience
Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
Patricia Recio-López, Ismael Valladolid‐Acebes, Philipp Hadwiger, Markus Hoßbach, Monika Krampert, Carla A. H. Prata, Per‐Olof Berggren, Lisa Juntti‐Berggren · 2022 · BioFactors
Cholesterol-Conjugated siRNA Silencing Tnf for the Treatment of Liver Macrophage-Mediated Acute Inflammation in Nonalcoholic Fatty Liver Disease
Kevin P. Craig, Marc T. Abrams, Mansoor M. Amiji · 2022 · Nucleic Acid Therapeutics
Proprotein Convertase Subtilisin Kexin 9 Inhibitors
Angela Pirillo, Alberico Luigi Catapano · 2018 · Cardiology Clinics
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Kazutoshi Sugiyama, Yoshifumi Saisho · 2018 · Diseases
Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease
Leo Francis Buckley, Salvatore Carbone, Ahmed Mohammed Aldemerdash, Nayyra Fatani, John R. Fanikos · 2018 · The American Journal of Medicine
Cancer biology functional genomics: From small RNAs to big dreams
Soumya Sundara Rajan, Katelyn R. Ludwig, Katherine L. Hall, Tamara L. Jones, Natasha J. Caplen · 2020 · Molecular Carcinogenesis
Introduction of 2-O-benzyl abasic nucleosides to the 3′-overhang regions of siRNAs greatly improves nuclease resistance
Yuki Nagaya, Yoshiaki Kitamura, Aya Shibata, Masato Ikeda, Yukihiro Akao, Yukio Kitade · 2017 · Bioorganic & Medicinal Chemistry Letters
Controlling Protein Expression by Delivery of RNA Therapeutics Using Lipid Nanoparticles
Paulo J.C. Lin, Ying K. Tam · 2019 · Elsevier eBooks
Gene Therapy in Pediatric Liver Disease
Andrés Fernando Muro, Lorenzo D’Antiga, Federico Mingozzi · 2019 · Springer eBooks
RNA Interference for the Masses? siRNA Targeting PCSK9 Promises Prevention of Cardiovascular Disease
Jonathan K. Watts, Ira S. Ockene · 2020 · Nucleic Acid Therapeutics
Cholesterol and alcohol
Andrew S. Bell, Emma M. O’Connell, Falk W. Lohoff · 2022 · Elsevier eBooks
CADD-engineered peptide protacs efficiently target PCSK9 for hypercholesterolemia in vivo
Gang Fan, W P Guo, Jingfen Lu, Yaohui He, Jinhui Zha, Qingping Zhang, Yijia Chen, Dong Tan, 唐志晗, Jing Yang et al. · 2025 · Metabolism
Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies
Zaheer Ahmad Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio · 2024 · Annals of Medicine and Surgery
2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories
Hesham Taha, Hossam Kandil, Hala Mahfouz Badran, Nabil Mahmoud Farag, Hazem Khamis, Gamila M. Nasr, Mina Samy, Moustafa Abdrabou, Mohamed Abuelezz, Mirna Mamdouh Shaker · 2024 · The Egyptian Heart Journal
Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates
Saket Agarwal, Elizabeth Taft, Micah Gauthier, Justin Darcy, Kira Buckowing, Daniel Berman, Wendell P. Davis, Arlin B. Rogers, Maja M. Janas · 2025 · Nucleic Acid Therapeutics
Treatment of heterozygous familial hypercholesterolemia: what does the future hold?
Georgios Polychronopoulos, Κωνσταντίνος Τζιόμαλος · 2020 · Expert Review of Clinical Pharmacology
Epigenetics and Noncoding RNA – Principles and Clinical Impact
Uwe Kornak, Oliver Bischof, Eric Hesse, Franz Josef Jakob, Regina Ebert, Hanna Taipaleenmäki · 2021 · Osteologie/Osteology
Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice
Yoshiyasu Minami, Daisuke Kinoshita, Yusuke Muramatsu, Takako Nagata, Junya Ako · 2022 · Journal of Asian Pacific Society of Cardiology
The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy
Piotr M. Wańczura, David Aebisher, Mateusz A. Iwański, Angelika Myśliwiec, Klaudia Dynarowicz, Dorota Bartusik‐Aebisher · 2024 · Biomedicines
The Role of Lipoprotein(a) in the Progression of Aortic Stenosis
Clay Sherrill, Lauren C. Ehrhardt-Humbert, Deeb N. Salem · 2025 · The American Journal of Medicine
Novel approaches to lipid-lowering therapy
D Brozin, Frederick Johan Raal · 2018 · South African Medical Journal
Liver-targeted RNAi Therapeutics: Principles and Applications
Kallanthottathil G. Rajeev, Muthiah Manoharan · 2019 · Royal Society of Chemistry eBooks
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
Johnathon Seth Parham, Anne Carol Goldberg · 2022 · Current Atherosclerosis Reports
Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist
Domenico Girelli, Fabiana Busti, Giacomo Marchi, Nicola Martinelli, Oliviero Olivieri · 2018 · Internal and Emergency Medicine
Una historia resumida. La inhibición de la PCSK9 y su desarrollo clínico
Jose Luis Lopez-Sendon, Almudena Castro, Regina Dalmau · 2017 · Revista Española de Cardiología Suplementos
Programmed Instability of Ligand Conjugation Manifold for Efficient Hepatocyte Delivery of Therapeutic Oligonucleotides
Chisato Terada, Fumito Wada, Mei Uchida, Yukari Yasutomi, Kaho Oh, Seiya Kawamoto, Yukina Kayaba, Asako Yamayoshi, Mariko Harada‐Shiba, Satoshi Obika et al. · 2021 · Nucleic Acid Therapeutics
Efficacy, benefit and safety of inclisiran
López-Miranda, José · 2024 · Clínica e Investigación en Arteriosclerosis (English Edition)
The N‐Acetylgalactosamine ‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
Dario E. Lehoux, David G. Kallend, Peter L. J. Wijngaard, Alan P. Brown, Brad R. Zerler · 2023 · Pharmacology Research & Perspectives
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention
Chukwuemezie Kamanu, Dean G. Karalis · 2025 · Current Atherosclerosis Reports
Update: Enzymatische Synthese für industrielle Anwendungen
Thomas Bayer, Shuke Wu, Radka Šnajdrová, Kai Baldenius, Uwe T. Bornscheuer · 2025 · Angewandte Chemie
Small interfering RNA effect on lipoprotein(a): a systematic review
Omar Almaadawy, Mohamed Hesn, Yomna Ayman Elsalamony, Omar Ayman Abobakr, Abdelrahman Elshimy, Khaled Alsayed Abualkhair, Mahmoud Mohamed Negm, Ahmed Yasser Shaban, Yakubu O. Bene-Alhasan, Frank Annie et al. · 2025 · The Egyptian Heart Journal
A systemically deliverable lipid-conjugated siRNA targeting DUX4 as an facioscapulohumeral muscular dystrophy therapeutic
Katelyn Daman, Jing Yan, Annabelle Biscans, Dimas Echeverria, Taisia Shmushkovich, Alexey D. Wolfson, Julia F. Alterman, Anastasia Khvorova, Charles P. Emerson · 2025 · Molecular Therapy — Methods & Clinical Development
Strategies for the delivery of RNA therapeutics to diseased heart tissue
Letizia Nicoletti, Martina Coletto, Giovanni Paolo Stola, Camilla Paoletti, Elena E. Marcello, Daniele Testore, Francesca Tivano, Alice Zoso, Clara Mattu, Valeria Chiono · 2025 · Expert Opinion on Drug Delivery
Design and systematic evaluation of novel chemical modification patterns enable the identification of a potent siRNA targeting PCSK9
Ze-Ao Huang, Shuo Yang, Guang-Shen Ji, Zhong-Cai Gao, Zhen-Min Li, Jie Wang, Fei‐Hai Yu, Geng-Shen Song · 2025 · Molecular Therapy — Methods & Clinical Development
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma
Kirit Singh, Matthew W. Foster, Marlene J. Violette, Anna M. Corcoran, Kelly M. Hotchkiss, Chelsea O. Railton, Emily E. Blandford, Kathryn E. Blethen, Elizabeth Louise Thomas, William C. McIntosh et al. · 2025 · Scientific Reports
Advanced multifunctional nano-delivery platform focusing on treating diseases related to lipid metabolism via targeted intervention in various lipid metabolic processes
Ying Xin Sun, Kai Yan, Yi Zhang, Yanqi Han, Long-Hui Hao, Yue Gao, Hongliang Wang, Hongqian Chu, Jun Ye, Yuling Liu et al. · 2025 · Military Medical Research
Inherited risk of coronary artery disease: redefining care with imaging and genetics
Nick S.R. Lan, Girish Dwivedi, Graham S. Hillis, Derek P. Chew, Bu Beng Yeap, Gemma A. Figtree, Amit V. Khera, Gerald Francis Watts, Abdul Rahman Ihdayhid · 2026 · Nature Reviews Cardiology
Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease
Han Gao, Da Pan, Hélder A. Santos · 2026 · Advanced Materials
Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction
Yuqi Yang, Min Qu, Tonghuan Xiao, Xinyang Han, Michael T. C. Ying · 2026 · Advanced Healthcare Materials
ORGAN THERAPEUTICS DURING EX-SITU DYNAMIC PRESERVATION. A LOOK INTO THE FUTURE
Paulo Ney Aguiar Martins, Serena Del Turco, Nicholas Gilbo · 2022 · European Journal of Transplantation
Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
Jelena Rakočević, Milan R. Dobric, Rada M. Vučić, Matija Furtula, Ivan V. Zaletel, Katarina Milutinović, Ana Ilijevski, Milica Labudović‐Borović, Miloje V. Tomasevic, Miloš Bajčetić · 2023 · International Journal of Molecular Sciences
Delivery of Rna Drugs: Beyond the Liver, More than Vaccine
Marwa G. Elnaggar, Yanying He, Yoon Yeo · 2023 · European Journal of Pharmaceutics and Biopharmaceutics
Inclisiran: the preclinical discovery and development of a novel therapy for the treatment of atherosclerosis
Donatos Tsamoulis, Lοukianos S. Rallidis, Constantine E. Kosmas · 2024 · Expert Opinion on Drug Discovery
Trends and Prospects of Low-Density Lipoprotein Cholesterol in Stroke: A Bibliometric Analysis
Bofeng Yang, Xianjun Ma, Yang Li, Guangrong Bian, Benyu Qiao, Hongxiang Lu, Zhuqing Wang, Tian Zhang, Ying Cheng · 2024 · Cureus
Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999–2018 study
Haonan Li, Song Zhao, Jiawen Wu, Jun Han, Yawei Xu, Shengfeng Shi, Yi Zhang · 2024 · Lipids in Health and Disease
Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database
Zitong Huang, Wenhui Zhang, Dong-Ze Wang, Yajuan Zhang, Yi-Bing Duan, Xinyang He, Yang-Xin Gao, Zhuo-Nan Jia, Xu Qian · 2024 · Expert Opinion on Drug Safety
RNA in the spotlight: the dawn of RNA therapeutics in the treatment of human disease
Konstantinos Stellos · 2017 · Cardiovascular Research
The year in cardiology 2017: prevention
Børge Grønne Nordestgaard, Francesco Cosentino, Ulf Landmesser, Ulrich Laufs · 2017 · European Heart Journal
Update on management of paediatric dyslipidaemia
Nidhi Bansal, Seema Kumar, Preneet Cheema Brar · 2022 · Current Opinion in Endocrinology Diabetes and Obesity
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Kohei Takata, Stephen James Nicholls · 2018 · American Journal of Cardiovascular Drugs
Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches
Forough Taheri, Eskandar Taghizadeh, Fatemeh Baniamerian, Daryoush Rostami, Ahmad Rozeian, Seyed Mohammad Gheibi Hayat, Tannaz Jamialahmadi, Željko Reiner, Amirhossein Sahebkar · 2022 · Endocrine Metabolic & Immune Disorders - Drug Targets
New and Emerging Therapies for Dyslipidemia
Alberto Zambon, Maurizio Rocco Averna, Laura D’Erasmo, Marcello Arca, Alberico Luigi Catapano · 2022 · Endocrinology and Metabolism Clinics of North America
Co-repressing immunometabolic processes in atherosclerosis
Sokrates Stein · 2022 · Cardiovascular Medicine
Investigational therapies for hypercholesterolemia
GERALD H. TOMKIN, Daphne Owens · 2017 · Expert Opinion on Investigational Drugs
Potent Efficacy of Computer-Aided Designed Peptide Degrader Drug on PCSK9-Mediated Hypercholesterolemia
Gang Fan, Jingfen Lu, Ruirong Tan, Weiming Guo, Hong Liang, Jinhui Zha, Zhi‐Han Tang, Jing Yang, Zhijian Yu, Miao Liu · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Cell and gene therapeutic approaches in non-alcoholic fatty liver disease
Mohadeseh Poudineh, Fatemeh Mohammadyari, Negin Parsamanesh, Tananz Jamialahmadi, Prashant Kesharwani, Amirhossein Sahebkar · 2025 · Gene
Small Interfering RNA Therapy Targeting the Long Noncoding RNA SMILR for Therapeutic Intervention in Coronary Artery Bypass Graft Failure
Simon Brown, Anna L. Malinowska, Matthew Bennett, Andrés F. Correa-Sánchez, Laia Linda Horcasitas Valencia, Aimee P Lucignoli, Anna Kate Barton, Laura Clark, Judith C. Sluimer, Scott Peter Webster et al. · 2025 · JACC Basic to Translational Science
Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective
Dandan Hu, Xu Deng, Mengwen Feng, Xinyue Zhang, Qingfeng He, Tao Wang, Zhen Feng · 2025 · Frontiers in Pharmacology
The Potential of Noncoding RNAs-siRNAs in Cancer Research and Therapy: Challenges and Solutions
Himanshu, Mudasir Bashir, Moien Rasheed Lone, Mohsin Maqbool · 2026 · Experientia supplementum
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Asahi Oshima, Patrick W.J.C. Serruys, Scot Garg, John William McEvoy, David A. Wood, Torsten Doenst, David Paul Taggart, John D. Puskas, Ajmal Shajahan, Faisal Sharif et al. · 2026 · EuroIntervention
HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics
Marion Mafham, Mohammed Zayed, Rory Collins, Marc Steven Sabatine, Jane Armitage, D Brittain, Bruno R. da Costa, F Chen, Michelle Abhayawardena Goonasekera, Michael Hill et al. · 2026 · American Heart Journal
Dyslipoproteinemia therapy with lipoprotein-apheresis and/or human monoclonal antibodies
Rolf Bambauer, Ralf Schiel · 2019 · Trends in Medicine
PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives
Jitendra Gupta, Reena Gupta · 2022 · Current Molecular Pharmacology
Therapeutic Strategies for Angiogenesis Based on Endothelial Cell Epigenetics
Yue Cai, Lihua Li, Chen Shao, Yiliu Chen, Zhongqun Wang · 2024 · Journal of Cardiovascular Translational Research
Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS
Xuezhong Shi, Ying Qiao, Yongli Yang, Nana Wang, Yi Zhang, Shangxin Shi, Guibin Shen, Xiaocan Jia · 2024 · Expert Opinion on Drug Safety
Single-Stranded Hairpin Loop RNAs (loopmeRNAs) Potently Induce Gene Silencing through the RNA Interference Pathway
Krishna Chaitanya Aluri, Dhrubajyoti Datta, Scott Waldron, Nate Taneja, June Qin, Daniel P. Donnelly, Christopher S. Theile, Dale C. Guenther, Lei Li, Joel M. Harp et al. · 2024 · Journal of the American Chemical Society
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Eligibility and Prescription Rates in Patients Presenting With Recurrent Acute Coronary Syndromes
William B He, D. Jape, Shane Nanayakkara, James A. Shaw · 2024 · Heart Lung and Circulation